FierceBiotech

Infinity Reports Topline Data from Phase 2 Study of Retaspimycin Hydrochloride, Its Hsp90 Inhibitor, in Patients with Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (INFI) today announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock ...
Nasdaq

Infinity Pharma (INFI) Stock Up on Advancing Cancer Study

Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
FierceBiotech

Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis

– Phase 2 Study of Duvelisib with Background Methotrexate in Patients with Moderate-to-Severe Rheumatoid Arthritis Did Not Meet Primary Endpoint – – Infinity to Continue Focusing Its Efforts on the ...
Auto Remarketing

Infiniti dealers post record high score in study of responsiveness to online leads

When it comes to responding to customers online, Infiniti dealers are No. 1, according to Pied Piper’s latest research. The luxury brand topped Volkswagen, Cadillac, Subaru and Polestar in the 2024 ...